- You can view the full Sarepta Therapeutics Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Following speculation that Sarepta Therapeutics's (SRPT) muscular dystrophy therapy is struggling to gain approval, Janney highlighted downside risk to the stock.
Sarepta (SRPT) stock is advancing in afternoon trading after a government website indicated the biopharmaceutical company is recruiting patients in its Phase III trials to treat Duchenne muscular dystrophy.